Jasper Therapeutics (NASDAQ:JSPR) Raised to “Strong-Buy” at Piper Sandler

Jasper Therapeutics (NASDAQ:JSPR) was upgraded by equities researchers at Piper Sandler to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

A number of other equities analysts have also commented on JSPR. Wall Street Zen raised shares of Jasper Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Royal Bank Of Canada set a $3.00 target price on shares of Jasper Therapeutics and gave the company a “sector perform” rating in a research note on Friday, May 15th. TD Cowen lowered Jasper Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.57.

Jasper Therapeutics Trading Down 7.7%

JSPR stock opened at $0.82 on Wednesday. Jasper Therapeutics has a one year low of $0.32 and a one year high of $3.14. The firm has a 50-day moving average of $0.58 and a two-hundred day moving average of $0.91. The firm has a market capitalization of $23.07 million, a PE ratio of -0.26 and a beta of 3.02.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Thursday, May 14th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.08. On average, equities research analysts anticipate that Jasper Therapeutics will post -1.67 earnings per share for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

Several large investors have recently made changes to their positions in the company. Engineers Gate Manager LP bought a new position in Jasper Therapeutics during the fourth quarter valued at approximately $26,000. Panagora Asset Management Inc. bought a new stake in Jasper Therapeutics in the fourth quarter worth approximately $35,000. Acadian Asset Management LLC acquired a new position in shares of Jasper Therapeutics during the 1st quarter worth $46,000. Voleon Capital Management LP acquired a new position in shares of Jasper Therapeutics during the 3rd quarter worth $50,000. Finally, Jain Global LLC bought a new position in shares of Jasper Therapeutics during the 4th quarter valued at $79,000. Institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.